Gilead Sciences shares are trading at a significant discount to analyst estimates of their intrinsic value, according to a recent analysis by Simply Wall St. The stock closed at $143.93 on March 8, 2026, with year-to-date returns of 18.4% and a 26.0% gain over the past year. Still, shorter-term performance shows a 3.4% decline over the last week and a 3.6% drop over the past month.
The analysis, which assigns Gilead a valuation score of 4 out of 6, suggests the company is undervalued. A Discounted Cash Flow (DCF) model estimates the intrinsic value of Gilead stock at approximately $290.68 per share, representing a 50.5% discount to the current market price. This calculation is based on projected free cash flows, with an estimated $9.4 billion in free cash flow over the last twelve months, rising to $15.66 billion by 2030 and $19.44 billion by 2035.
For profitable companies like Gilead, the Price-to-Earnings (P/E) ratio is a key valuation metric. Gilead currently trades at a P/E ratio of 20.99x, closely aligned with the biotechnology industry average of 20.98x but significantly below the peer group average of 42.42x. Simply Wall St’s proprietary “Fair Ratio” for Gilead is 28.09x, suggesting the stock is trading below a reasonable valuation given its growth profile and risk factors.
Simply Wall St’s Community page offers investors the opportunity to create “Narratives” – customized financial forecasts based on individual assumptions about the company’s future performance. A bullish narrative, assuming 6.63% annual revenue growth, estimates a fair value of $159.00 per share, representing a 9.5% premium to the current price. This scenario anticipates earnings of $10.8 billion by 2028 and profit margins around 32%. Conversely, a more cautious narrative, projecting 3.69% revenue growth, arrives at a fair value of $132.57 per share, an 8.6% discount to the current price. This scenario anticipates earnings of $10.0 billion by 2028 and profit margins near 31%.
These narratives highlight the sensitivity of Gilead’s valuation to assumptions about revenue growth, profit margins, and future P/E ratios. Investors are encouraged to explore these narratives and adjust the assumptions to reflect their own perspectives on the company’s prospects in HIV, PrEP, and oncology.
